Windlas Biotech is a Dehradun-based pharmaceutical contract development and manufacturing organization that makes oral solids, oral liquids and injectables for other pharma companies, alongside a trade generics business sold into Tier 2 and Tier 3 Indian towns and a small exports vertical focused on semi-regulated markets. The money is made primarily in the Generic Formulations CDMO segment, roughly 73% of revenue, which grew 29% year-on-year to INR207 crores in Q1 FY27 out of a record INR248 crore quarter, the fourteenth consecutive record quarter. Trade Generics and Institutional contributed INR30 crores in Q1 FY27 after the discontinuation of codeine-based products, and exports grew 79% to INR11 crores. The economics are cost-plus with transparent pass-through of API prices, so growth is volume-led rather than price-led. Adjusted EBITDA margin was 13.4% in FY26 and about 13.7% in Q1 FY27 excluding ESOP cost, which places the business in the average-to-good band for Indian contract manufacturing rather than the exceptional zone above 25%. That is not a flaw unique to Windlas; it is what the CDMO model pays, and the question is persistence and trajectory, not peak level.
The durability question is answered by evidence rather than assertion. The company supplies around 16 of India's top pharma companies, has never lost an account on performance issues over more than 20 years, and its plants are audited by customers 70 to 80 times a year. Customer concentration is unusually low for a CDMO: the largest customer was 6.5% of FY26 revenue and the top ten about 32%, meaning no single brand decision can break the model. New dosage form entry carries real barriers of R&D, stability batches, regulatory approvals and per-customer plant qualification, which is why brownfield oral solids additions take about a year from planning to online. The structural tailwind is regulatory: Schedule M enforcement without further extensions pressures an industry management describes as having 13,000-plus fragmented players toward consolidation, favoring capital-rich, audit-tested operators. The honest caveat is that trade generics competition is intensifying as larger listed pharma companies enter, and the 150-to-200-product basket approach there is a strategy differentiator but not an unassailable one.
The inflection is mechanical and dated. Plant 6, an oral solids expansion costing roughly INR50-60 crores, reached mechanical completion with validations and customer audits underway, and commercialization is targeted for the end of H1 FY27 within a 15-day tolerance. Once online, stated revenue capability rises to about INR1,100 crores excluding injectables, plus roughly INR100 crores from the injectables facility, with management guiding a further 10-15% unlock through efficiency initiatives and INR100-150 crores possible from Plant 6 debottlenecking. Current utilization sits near 65% against a practical ceiling of about 70% for this business model, which is precisely why the new capacity matters now. The concrete picture 18-24 months out is a company running at or near full utilization on roughly INR1,200 crore-plus of nameplate capability, absorbing incremental Plant 6 depreciation of about INR30 million per quarter from Q2 FY27 fully reflected by Q3, with trade generics rebuilt after the roughly INR55 crore annual codeine hole via SKU expansion across its 150-200 product basket, exports compounding off a Philippines GMP approval for injectables, and a possible GLP-1 vial-filling option if brand owners outsource volumes. Management has explicitly guided no major organic capex in FY27 beyond INR12-15 crores of maintenance spend, with any new capacity decision deferred to FY28.
The walk-talk record is clean. Across the November 2025 through August 2026 calls, management repeatedly committed that Plant 6 would be mechanically complete by end-FY26 and commercialized in H1 FY27, that injectables would scale after an early ramp lag acknowledged in November 2025, and that margins would improve gradually without quantifying when. Delivery has matched promise: mechanical completion happened on schedule, Q1 FY27 revenue grew 18% with EBITDA ex-ESOP up 26% and PAT ex-ESOP up 37%, working capital days have held at roughly 20-25 for three years against a prior base near 40, and net liquidity stood at INR251 crores at FY26-end with ROCE and ROE above 25%. Capital allocation has been shareholder-friendly without dilution: an INR47 crore buyback completed without promoter participation, an INR13 crore dividend proposed for FY26, and ESOPs covering about 100 of 1,100 employees whose non-cash cost of INR7.2 crores in Q1 FY27 is transparently excluded from adjusted figures. No guidance has been cut and none was ever given formally, which limits verification but also means no broken promises exist on record.
The earnings path is visible enough to quantify: capacity of roughly INR1,100 crores ex-injectables plus INR100 crores injectables, stretched another 10-15% by efficiency work, growing at the recent high-teens rate implies revenue approaching or exceeding INR1,000 crores annualized run-rate during FY28, with ex-ESOP EBITDA margins holding in the 13.5-14% range near term before mix and operating leverage push them higher once Plant 6 depreciation is absorbed. For this to hold, three things must be true: Plant 6 passes customer plant-level audits and ramps on schedule, new customer acquisition fills the capacity since existing utilization is already near the model's ceiling, and the codeine substitution backfills within the few quarters management promised. The single most important falsifier is the gap between stated capacity and realized revenue: if Q2 and Q3 FY27 show Plant 6 online but revenue growth decelerating below the mid-teens while trade generics stays soft, the problem is commercial conversion rather than construction, and the operating-leverage story breaks there. Watch the quarterly revenue print against the INR1,100 crore capability and the pace of trade generics recovery above the INR45-50 crore quarterly range.
companyname: Windlas Biotech Limited ticker: WINDLAS sector: Pharmaceuticals - Contract Development and Manufacturing (CDMO) Windlas Biotech is a contract development and manufacturing organization (CDMO) that makes pharmaceutical formulations on behalf of other companies. When an Indian pharma company wants to launch a product without building its own factory, it hands Windlas the molecule, and Windlas develops the formulation, runs the regulatory filings, and manufactures at scale. The compan...
Read the full report →capex, margin expansion
Plant 6 commercialization expected by H1 FY27 to deliver INR1,000 cr revenue excluding injectables
Guidance no_dataconsistent
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Windlas Biotech Limited and 4,900+ companies.
5-day free pass. No card required.